Warfarin was initially marketed as a pesticide for mice. A few years after being introduced, it was found to be effective and safe in preventing thrombosis and embolism. Warfarin was then approved to be a medication in early 1950s and has been used ever since. Common brand names are Coumadin, Warik, and Zyfarin. Warfarin is classified as a Coumarin derivative and an anticoagulant.
Warfarin is used as prophylaxis and treatment of venous thrombosis and pulmonary embolism. It is used in the treatment of thromboembolism associated with chronic atrial fibrillation. Warfarin is used as adjunct in treatment of coronary occlusion. It is also used as a prophylaxis and treatment of thromboembolic complications associated with cardiac valve replacement. Warfarin reduces risk of death, recurrent myocardial infarction, stroke, and embolization after myocardial infarction.
Warfarin can be used as a prohylaxis for recurrent cerebral embolism, myocardial reinfarction, and treatment adjunct in transient ischemic attacks.
Alert: Dosage is highly individualized and is based on each individual’s prothrombin time (PT), INR (International Normalized Ratio).
PO: ADULTS, ELDERLY: Initially, 5-15 mg per day for 2-5 days, then adjust based on INR. MAINTENANCE: 2-10 mg per day. CHILDREN: Initially, 0.1-0.2 mg per kg. Maximum: 10 mg. MAINTENANCE: 0.05-0.34 mg/kg/day.
PO/IV: ADULTS: 2-5 mg per day (maintenance).
Warfarin interferes with hepatic synthesis of vitamin K-dependent clotting factors, resulting in depletion of coagulation factors II, VII, IX, and X. Prevents further extension of formed existing clot, prevention of new clot formation, and secondary thromboembolic complications.
Do you have any suggestions on improving our site, research materials that we can consider for our future updates? You can contact and send research materials to NC101 here.